Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

Oruka Therapeutics' Senior Vice President of Finance Arjun Agarwal sold 9,854 shares worth approximately $687,000 in mid-June 2026, reducing his direct holdings by 36.83%. The sale occurred after the stock had already surged 450% over the previous year and two weeks before it reached nearly 700% gains. The insider sale follows positive Phase 2 clinical data for the company's monoclonal antibody therapies ORKA-001 and ORKA-002, though the company continues to operate at a net loss with quarterly losses widening to $31.8 million.

06/27/2026, 3:28 PM • The Motley Fool

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, sold 10,290 shares worth approximately $608,000 on May 18, 2026, at a weighted average price of $59.07 per share. The sale was part of a pre-arranged Rule 10b5-1 trading plan and should not concern investors, as it was non-discretionary. The transaction came after the stock surged 457.71% over one year, driven by encouraging clinical trial data and a $700 million public offering announced in April.

06/24/2026, 5:24 PM • The Motley Fool

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

Carl Dambkowski, Director of Oruka Therapeutics, sold 105,000 shares worth approximately $6.19 million on May 21, 2026, reducing his direct holdings by 58.74%. Despite the significant sale, Dambkowski retains approximately 73,743 shares and derivative securities. The sale was executed through the exercise and immediate sale of vested options. Oruka, a clinical-stage biotech company developing monoclonal antibody therapeutics, has seen its stock surge 407% over the past 12 months following positive clinical trial results for its lead candidate ORKA-001 in psoriasis treatment.

05/31/2026, 10:21 AM • The Motley Fool

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

Oruka Therapeutics reported strong phase 2a trial results for ORKA-001, showing 63.5% PASI 100 response rates compared to Skyrizi's typical 51%, potentially threatening AbbVie's $17.6 billion psoriasis drug. However, the article argues AbbVie remains a solid long-term investment due to its diverse pipeline, other growth drivers like Qulipta and Botox, and its status as a Dividend King.

05/11/2026, 5:15 PM • The Motley Fool

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, generating approximately $700.4 million in gross proceeds. The offering is expected to close on or about April 30, 2026, with underwriters granted a 30-day option to purchase up to 1.45 million additional shares.

04/28/2026, 7:42 PM • GlobeNewswire

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics (NASDAQ: ORKA), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and inflammatory conditions, announced a proposed $500 million underwritten public offering of common stock and pre-funded warrants. The company also expects to grant underwriters a 30-day option to purchase an additional $75 million in shares. The offering is subject to market conditions and SEC approval.

04/27/2026, 4:17 PM • Benzinga

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

04/14/2026, 1:00 PM • GlobeNewswire